FDA advises monitoring of patients on Chantix and Zyban following suicide reports
스크롤 이동 상태바
FDA advises monitoring of patients on Chantix and Zyban following suicide reports
기자명
메디칼라이터팀
입력 2009.07.02 00:00
수정 2009.07.02 23:59
댓글 0
Patients taking Pfizer"s Chantix [varenicline] and GlaxoSmithKline"s Zyban [bupropion] should be monitored due to a number of suicide reports, according to the FDA. According to, Dr. Curtis J. Rosebraugh, director of a drug evaluation office at the Food and Drug Administration, symptoms linked to the drugs resemble those of nicotine withdrawal but that sometimes the benefits outweigh the risks. Both Pfizer and Glaxo claim their drugs do not cause suicidal thoughts and both will add black-box warnings to the drugs packaging. The FDA has received 317 reports of suicidal incidents amongst patients on the drugs. An additional study on Chantix and Zyban to determine the extent of the side effects is required by regulators.